Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium chloride + dextrose monohydrate + sodium lactate + sodium chloride + calcium chloride is a **multi-electrolyte peritoneal dialysis solution** marketed as **Delflex** by Fresenius Medical Care for patients with chronic kidney failure maintained on peritoneal dialysis. The formulation contains dextrose monohydrate as the osmotic agent together with sodium chloride, sodium lactate, calcium chloride, and magnesium chloride to create a dialysate that exchanges solutes and water across the peritoneal membrane. Its therapeutic effect is primarily physicochemical rather than receptor-mediated: the hyperosmolar dextrose solution promotes ultrafiltration, while the electrolyte and lactate components help maintain dialysate composition and buffering during dialysis. It is administered intraperitoneally as a sterile solution and has been marketed in multiple concentrations and ionic variants, including low magnesium and low calcium presentations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium chloride + dextrose monohydrate + sodium lactate + sodium chloride + calcium chloride.